Adcetris: Additional Ph III ALCANZA data

Additional data from the open-label, international Phase III ALCANZA trial in 131 patients with CD30-positive CTCL who received prior systemic therapy or radiation therapy showed that 1.8 mg/kg IV

Read the full 297 word article

User Sign In